English
Exciting news in leprosy detection and surveillance. Think positive!
Although considered an extinct calamity, leprosy is an infectious disease still present in more than hundred countries.
Seeking the source of tuberculosis drug resistance
A targeted deep sequencing assay identifies multidrugresistant tuberculosis strains responsible for silent outbreaks
Yes we can, end TB!
For over a decade, GenoScreen has been committed to the fight against tuberculosis (TB), one of the deadliest infectious diseases in the world. The company's journey began with the groundbreaking development of MIRU-VNTR typing kits in 2013 which marked a turning point in TB research and control by enabling rapid and accurate identification of TB strains. This breakthrough technology provided an unparalleled level of resolution in characterizing TB strains, essential for the management and control of TB outbreaks, allowing researchers and public health authorities to track the spread of the disease more efficiently and prevent further outbreaks.
GenoScreen becomes a Certified Service Provider by Oxford Nanopore Technologies
GenoScreen is now a certified service provider of Oxford Nanopore Technologies.
GenoScreen and Illumina Partner to Expand Access to Genomic Testing for Multidrug-Resistant Tuberculosis
GenoScreen, world specialist in TB genomic solutions, and Illumina partner to expand access to a package combining Deeplex® Myc-TB assay and Illumina sequencing products.
Meet us at the 18th International Symposium on Microbial Ecology (ISME), Lausanne – Switzerland
The new edition of the International Symposium on Microbial Ecology a staple meeting in the field, will cover many topics, in environment, human and animal health, and bioprocesses.
Dr Philip Supply receives the Gardner Middlebrook Lifetime Achievement Award 2022
Dr Philip Supply, Director of Research at the CNRS and Scientific Adviser at GenoScreen, has received the prestigious Gardner Middlebrook Lifetime Achievement Award at the 42nd Annual Congress of the European Society of Mycobacteriology (ESM) on 26 June 2022 in Bologna – Italy.
Subcategories
GenoScreen
Partners
GenoScreen develops its technologies and know-how in genomics within a dense, well-structured network of partners.
These collaborations co-fund ambitious research programs and jointly develop innovative technologies: an effective and agile strategy that opens up new opportunities for our staff.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.